← Back to Search

HMG-CoA Reductase Inhibitor

Moderate to High Statin Treatment in Participants with Coronary Artery Plaque for Cardiovascular Disease

Phase 4
Waitlist Available
Led By Nehal N Mehta, M.D.
Research Sponsored by National Heart, Lung, and Blood Institute (NHLBI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

Study Summary

This trial will study how well CT scanning can determine if an individual's arterial plaque has decreased while taking statins.

Eligible Conditions
  • Cardiovascular Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To prospectively compare the change in coronary artery plaque burden determined by CCTA in asymptomatic individuals with moderate CVD risk treated either a) according to 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athe...
Secondary outcome measures
long-term effects of the statin therapy

Trial Design

1Treatment groups
Experimental Treatment
Group I: Moderate to High Statin Treatment in Participants with Coronary Artery PlaqueExperimental Treatment4 Interventions
Participants with coronary artery plaque will receive moderate to high statin treatment at either 20-40 mg once daily Rosuvastatin or 40-80 mg once daily of Atorvastatin.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rosuvastatin
2019
Completed Phase 4
~3150
Atorvastatin
1998
Completed Phase 4
~10900

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)Lead Sponsor
3,834 Previous Clinical Trials
47,310,556 Total Patients Enrolled
Nehal N Mehta, M.D.Principal InvestigatorNational Heart, Lung, and Blood Institute (NHLBI)
3 Previous Clinical Trials
766 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Journal of the American College of CardiologyJournal
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Stone, Neil J., Jennifer G. Robinson, Alice H. Lichtenstein, C. Noel Bairey Merz, Conrad B. Blum, Robert H. Eckel, Anne C. Goldberg, et al.. 2014. “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults”. Journal of the American College of Cardiology. Elsevier BV. doi:10.1016/j.jacc.2013.11.002.
AtherosclerosisJournal
Atherosclerotic Coronary Plaque Regression and the Risk of Adverse Cardiovascular Events: A Meta-regression of Randomized Clinical Trials
D'Ascenzo, Fabrizio, Pierfrancesco Agostoni, Antonio Abbate, Davide Castagno, Michael J. Lipinski, George W. Vetrovec, Giacomo Frati, et al.. 2013. “Atherosclerotic Coronary Plaque Regression and the Risk of Adverse Cardiovascular Events: A Meta-regression of Randomized Clinical Trials”. Atherosclerosis. Elsevier BV. doi:10.1016/j.atherosclerosis.2012.10.065.
The LancetJournal
Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Primary Prevention: An Analysis from the JUPITER Trial
Ridker, Paul M, Aruna Pradhan, Jean G MacFadyen, Peter Libby, and Robert J Glynn. 2012. “Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Primary Prevention: An Analysis from the JUPITER Trial”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(12)61190-8.
Journal of the American College of CardiologyJournal
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Stone, Neil J., Jennifer G. Robinson, Alice H. Lichtenstein, C. Noel Bairey Merz, Conrad B. Blum, Robert H. Eckel, Anne C. Goldberg, et al.. 2014. “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults”. Journal of the American College of Cardiology. Elsevier BV. doi:10.1016/j.jacc.2013.11.002.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top